Gavin MacBeath, PhD
Affiliations: | Chemistry and Chemical Biology | Harvard University, Cambridge, MA, United States |
Area:
Protein SystemsWebsite:
http://macbeath.hms.harvard.edu/Google:
"Gavin MacBeath"Mean distance: 7.11 | S | N | B | C | P |
Parents
Sign in to add mentor| Donald M. Hilvert | grad student | 1997 | Scripps Institute | |
| (Evolutionary Approaches to the Design of Protein Receptors and Catalysts) | ||||
| Stuart L. Schreiber | post-doc | 2001 | Harvard | |
Children
Sign in to add trainee| Jiunn-Ren Chen | grad student | 2008 | Harvard |
| Andrew G. Gordus | grad student | 2008 | Harvard |
| Michael A. Stiffler | grad student | 2008 | Harvard |
| Tanya L. Knickerbocker | grad student | 2009 | Harvard |
| Jordan A. Krall | grad student | 2009 | Harvard |
| Elsa M. Beyer | grad student | 2010 | Harvard |
| Ethan S. Karp | grad student | 2010 | Harvard |
| Alexis L. Kaushansky | grad student | 2010 | Harvard |
| Grigoriy Koytiger | grad student | 2013 | Harvard |
| Albert S. Ye | grad student | 2013 | Harvard |
| Richard Baker Jones | post-doc | 2002-2006 | Harvard |
| Taran Gujral | post-doc | 2008-2016 | Harvard (Cell Biology Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Casaletto JB, Geddie ML, Abu-Yousif AO, et al. (2019) MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proceedings of the National Academy of Sciences of the United States of America |
| Hass H, Masson K, Wohlgemuth S, et al. (2018) Abstract 1312: Predicting ligand-dependent tumors from multi-dimensional signaling features Cancer Research. 78: 1312-1312 |
| Mathews S, Finn G, Kudla AJ, et al. (2017) Abstract A19: Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab Clinical Cancer Research. 23 |
| Finn G, Zhang H, Blois A, et al. (2017) Abstract A14: A randomized trial of exemestane +/- seribantumab (MM-121) in postmenopausal women with locally advanced or metastatic ER/PR+ HER2- breast cancer: Final analysis and extended subgroup analysis Clinical Cancer Research. 23 |
| Curley MD, Sabnis GJ, Wille L, et al. (2015) Seribantumab, an anti-ERBB3 antibody, delays the onset of resistance and restores sensitivity to letrozole in an estrogen receptor-positive breast cancer model. Molecular Cancer Therapeutics |
| Yarar D, Lahdenranta J, Kubasek W, et al. (2015) Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells. Molecular Cancer Therapeutics |
| Masson K, Grantcharova V, Burenkova O, et al. (2015) Abstract LB-243: The ErbB3-targeting antibody MM-121 (seribantumab) reverses heregulin-driven resistance to multiple chemotherapies on tumor cell growth Cancer Research. 75 |
| Abu-Yousif AO, Casaletto JB, Masson K, et al. (2015) Abstract 1690: Mechanistic characterization of MM-131, a bispecific antibody that blocks c-Met signaling through concurrent targeting of EpCAM Cancer Research. 75: 1690-1690 |
| Wainszelbaum MJ, Fessler J, Lahdenranta J, et al. (2015) Abstract LB-C25: Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands Molecular Cancer Therapeutics. 14 |
| Gujral TS, Chan M, Peshkin L, et al. (2014) A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 159: 844-56 |